Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

By The ASCO Post Staff Posted: 9/18/2022 11:47:00 AM Last Updated: 9/19/2022 8:37:19 AM In a large study led by researchers at the American...

In patients with resectable, stage IIIA non–small cell lung cancer (NSCLC), the addition of neoadjuvant nivolumab to platinum-based chemotherapy significantly improved overall survival compared...

By The ASCO Post Staff Posted: 9/23/2022 10:12:00 AM Last Updated: 9/23/2022 9:59:30 AM Physical activity may be associated with improved outcomes for patients...

By Matthew Stenger Posted: 9/27/2022 11:52:00 AM Last Updated: 9/27/2022 11:50:50 AM In a study (ABCD; Alleviating Breathlessness in Cancer Patients with Dexamethasone) reported...

Perhaps the best known of all cancer predisposition genes are inherited mutations in the genes BRCA1 and BRCA2. They were originally associated with an...

Despite a significant potential for cure, relapsed and refractory large B-cell lymphomas (LBCL) comprise the most common cause of lymphoma-related mortality. Sequential relapses reflect...

By The ASCO Post Staff Posted: 9/22/2022 12:02:00 PM Last Updated: 9/22/2022 2:37:07 PM On September 21, the U.S. Food and Drug Administration (FDA)...

The addition of the CTLA-4 inhibitor tremelimumab to durvalumab and chemotherapy in the first-line setting has already demonstrated an overall survival and progression-free survival...

By Matthew Stenger Posted: 9/20/2022 10:29:00 AM Last Updated: 9/20/2022 10:21:38 AM In a Dutch prospective observational cohort study reported in JAMA Oncology, Haggenburg...

  • 1572657160407990273 Profile photo of Madelyn

    Antibody Response to Three-Dose COVID-19 mRNA-1273 Vaccination Schedule in Immunocompromised Patients With Hematologic Cancers https://t.co/ISUNORYVE8 #COVID19 #vaccination #hematology #immunocompromised #lymsm #leusm - view on twitter

By Matthew Stenger Posted: 9/21/2022 2:39:00 PM Last Updated: 9/21/2022 1:48:58 PM As reported in The Lancet by Livingstone et al, the final analysis...